.png){kind=icon}
.png){kind=icon}
Return
Beyond HLA-Ia: A multidimensional framework for Neoantigen immunotherapy
.png){kind=icon}
PRE
AI
L
C
Y
L
P
DOI：10.1016/j.cellimm.2026.105112.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Glioma neoantigen immunotherapy is fundamentally constrained by HLA-Ia loss and impaired cellular immune surveillance. • HLA-E, a non-classical HLA-Ib molecule functions as an alternative antigen presentation platform that reshapes NK and CD8+ T-cell responses through the NKG2A axis. • γδ T cells provide an HLA-independent effector arm that complements neoantigen-driven adaptive immunity under immune escape conditions. • AI-assisted neoantigen engineering and BBB-penetrating delivery technologies enable translational realization of non-classical HLA- and γδ T-cell–based strategies. • A multidimensional cellular immune framework is proposed to overcome immune evasion in gliomas.
Keywords:
HLA-E
γδ T cells
neoantigen immunotherapy
NKG2A axis
glioma
Journal
IF:
2.9
Papers:
3.6K
Citations:
6.1K
Organization
No organization information available
Cited Papers